Banks - Regional
Compare Stocks
4 / 10Stock Comparison
SHFS vs LGND vs PRGO vs INVA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Drug Manufacturers - Specialty & Generic
Biotechnology
SHFS vs LGND vs PRGO vs INVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Banks - Regional | Biotechnology | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $1M | $4.13B | $1.61B | $1.93B |
| Revenue (TTM) | $18M | $251M | $4.18B | $424M |
| Net Income (TTM) | $-53M | $49M | $-1.82B | $504M |
| Gross Margin | 104.7% | 85.9% | 34.2% | 76.2% |
| Operating Margin | -24.2% | 7.0% | -4.1% | 14.8% |
| Forward P/E | — | 23.6x | 5.6x | 11.9x |
| Total Debt | $12M | $7M | $3.97B | $269M |
| Cash & Equiv. | $2M | $72M | $532M | $551M |
SHFS vs LGND vs PRGO vs INVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 21 | May 26 | Return |
|---|---|---|---|
| SHF Holdings, Inc. (SHFS) | 100 | 0.2 | -99.8% |
| Ligand Pharmaceutic… (LGND) | 100 | 159.0 | +59.0% |
| Perrigo Company plc (PRGO) | 100 | 28.6 | -71.4% |
| Innoviva, Inc. (INVA) | 100 | 149.4 | +49.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SHFS vs LGND vs PRGO vs INVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SHFS lags the leaders in this set but could rank higher in a more targeted comparison.
LGND is the #2 pick in this set and the best alternative if growth and momentum is your priority.
- 27.3% revenue growth vs SHFS's -9.2%
- +99.1% vs SHFS's -81.8%
PRGO is the clearest fit if your priority is income & stability.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Lower P/E (5.6x vs 11.9x)
- 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
INVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 18.5%, EPS growth 8.2%, 3Y rev CAGR 8.7%
- 94.9% 10Y total return vs LGND's 73.0%
- Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
- Beta 0.13, current ratio 14.64x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.3% revenue growth vs SHFS's -9.2% | |
| Value | Lower P/E (5.6x vs 11.9x) | |
| Quality / Margins | 118.9% margin vs SHFS's -262.5% | |
| Stability / Safety | Beta 0.13 vs SHFS's 1.87 | |
| Dividends | 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +99.1% vs SHFS's -81.8% | |
| Efficiency (ROA) | 32.4% ROA vs SHFS's -389.6%, ROIC 14.2% vs -13.7% |
SHFS vs LGND vs PRGO vs INVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SHFS vs LGND vs PRGO vs INVA — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INVA leads in 3 of 6 categories
PRGO leads 2 • SHFS leads 0 • LGND leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 227.0x SHFS's $18M. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to SHFS's -2.6%. On growth, LGND holds the edge at +122.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $18M | $251M | $4.2B | $424M |
| EBITDAEarnings before interest/tax | -$11M | $52M | $58M | $86M |
| Net IncomeAfter-tax profit | -$53M | $49M | -$1.8B | $504M |
| Free Cash FlowCash after capex | -$5M | $31M | $108M | $181M |
| Gross MarginGross profit ÷ Revenue | +104.7% | +85.9% | +34.2% | +76.2% |
| Operating MarginEBIT ÷ Revenue | -24.2% | +7.0% | -4.1% | +14.8% |
| Net MarginNet income ÷ Revenue | -2.6% | +19.3% | -43.5% | +118.9% |
| FCF MarginFCF ÷ Revenue | +2.3% | +12.2% | +2.6% | +42.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +122.8% | -7.2% | +10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -53.8% | +15.6% | -56.4% | +4.0% |
Valuation Metrics
PRGO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than LGND's 322.1x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1M | $4.1B | $1.6B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $11M | $4.1B | $5.1B | $1.7B |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | -956.05x | -1.14x | 6.91x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 23.65x | 5.56x | 11.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.67x |
| EV / EBITDAEnterprise value multiple | — | 322.10x | 7.42x | 8.10x |
| Price / SalesMarket cap ÷ Revenue | 0.07x | 24.74x | 0.38x | 4.55x |
| Price / BookPrice ÷ Book value/share | — | 4.63x | 0.55x | 1.65x |
| Price / FCFMarket cap ÷ FCF | 3.15x | 53.41x | 11.12x | 9.88x |
Profitability & Efficiency
INVA leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-8 for SHFS. LGND carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), LGND scores 5/9 vs PRGO's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.6% | +5.1% | -50.7% | +46.5% |
| ROA (TTM)Return on assets | -3.9% | +3.3% | -19.8% | +32.4% |
| ROICReturn on invested capital | -13.7% | -2.3% | +3.7% | +14.2% |
| ROCEReturn on capital employed | -13.1% | -2.7% | +4.3% | +12.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 4 | 5 |
| Debt / EquityFinancial leverage | — | 0.01x | 1.35x | 0.23x |
| Net DebtTotal debt minus cash | $10M | -$65M | $3.4B | -$282M |
| Cash & Equiv.Liquid assets | $2M | $72M | $532M | $551M |
| Total DebtShort + long-term debt | $12M | $7M | $4.0B | $269M |
| Interest CoverageEBIT ÷ Interest expense | -17.46x | 22.69x | -7.20x | 63.45x |
Total Returns (Dividends Reinvested)
Evenly matched — LGND and INVA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INVA five years ago would be worth $19,437 today (with dividends reinvested), compared to $24 for SHFS. Over the past 12 months, LGND leads with a +99.1% total return vs SHFS's -81.8%. The 3-year compound annual growth rate (CAGR) favors LGND at 39.5% vs SHFS's -64.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -55.3% | +10.6% | -13.5% | +14.7% |
| 1-Year ReturnPast 12 months | -81.8% | +99.1% | -51.2% | +21.7% |
| 3-Year ReturnCumulative with dividends | -95.4% | +171.6% | -58.1% | +95.2% |
| 5-Year ReturnCumulative with dividends | -99.8% | +61.0% | -60.1% | +94.4% |
| 10-Year ReturnCumulative with dividends | -99.8% | +73.0% | -77.7% | +94.9% |
| CAGR (3Y)Annualised 3-year return | -64.1% | +39.5% | -25.2% | +25.0% |
Risk & Volatility
INVA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than SHFS's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INVA currently trades 90.7% from its 52-week high vs SHFS's 5.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 0.99x | 1.18x | 0.13x |
| 52-Week HighHighest price in past year | $9.19 | $247.38 | $28.44 | $25.15 |
| 52-Week LowLowest price in past year | $0.38 | $98.89 | $9.23 | $16.52 |
| % of 52W HighCurrent price vs 52-week peak | +5.1% | +85.0% | +41.2% | +90.7% |
| RSI (14)Momentum oscillator 0–100 | 45.4 | 59.3 | 60.9 | 39.9 |
| Avg Volume (50D)Average daily shares traded | 270K | 226K | 3.4M | 621K |
Analyst Outlook
PRGO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: LGND as "Buy", PRGO as "Hold", INVA as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 27.3% for LGND (target: $268). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $267.75 | $20.00 | $37.67 |
| # AnalystsCovering analysts | — | 17 | 36 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — | +9.8% | — |
| Dividend StreakConsecutive years of raises | — | 1 | 10 | 0 |
| Dividend / ShareAnnual DPS | — | — | $1.15 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +0.2% |
INVA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
SHFS vs LGND vs PRGO vs INVA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SHFS or LGND or PRGO or INVA a better buy right now?
For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.
3% revenue growth year-over-year, versus -9. 2% for SHF Holdings, Inc. (SHFS). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SHFS or LGND or PRGO or INVA?
On forward P/E, Perrigo Company plc is actually cheaper at 5.
6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SHFS or LGND or PRGO or INVA?
Over the past 5 years, Innoviva, Inc.
(INVA) delivered a total return of +94. 4%, compared to -99. 8% for SHF Holdings, Inc. (SHFS). Over 10 years, the gap is even starker: INVA returned +94. 9% versus SHFS's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SHFS or LGND or PRGO or INVA?
By beta (market sensitivity over 5 years), Innoviva, Inc.
(INVA) is the lower-risk stock at 0. 13β versus SHF Holdings, Inc. 's 1. 87β — meaning SHFS is approximately 1385% more volatile than INVA relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — SHFS or LGND or PRGO or INVA?
By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.
3% versus -9. 2% for SHF Holdings, Inc. (SHFS). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, INVA leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SHFS or LGND or PRGO or INVA?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus -262. 5% for SHF Holdings, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -24. 2% for SHFS. At the gross margin level — before operating expenses — SHFS leads at 104. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SHFS or LGND or PRGO or INVA more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 23. 6x for Ligand Pharmaceuticals Incorporated — 18. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — SHFS or LGND or PRGO or INVA?
In this comparison, PRGO (9.
8% yield) pays a dividend. SHFS, LGND, INVA do not pay a meaningful dividend and should not be held primarily for income.
09Is SHFS or LGND or PRGO or INVA better for a retirement portfolio?
For long-horizon retirement investors, Innoviva, Inc.
(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). SHF Holdings, Inc. (SHFS) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, SHFS: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SHFS and LGND and PRGO and INVA?
These companies operate in different sectors (SHFS (Financial Services) and LGND (Healthcare) and PRGO (Healthcare) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SHFS is a small-cap quality compounder stock; LGND is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; INVA is a small-cap high-growth stock. PRGO pays a dividend while SHFS, LGND, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.